Nyxoah (NYXH) said Tuesday it is actively addressing the validation of a process used with a component of its Genie obstructive sleep apnea treatment device at its US manufacturing site ahead of potential US Food and Drug Administration marketing approval.
The company said it is confident of completing the validation in the near term, with the application approval likely in Q2.
The FDA late last month issued an approvable letter with regard to Genio's pre-market approval application.
Nyxoah shares were up nearly 23% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。